Torcetrapib manufacturers
- Torcetrapib
-
- $0.00 / 1g
-
2021-07-20
- CAS:262352-17-0
- Min. Order: 1g
- Purity: 99%
- Supply Ability: 2000tons
|
| | Torcetrapib Basic information |
| | Torcetrapib Chemical Properties |
| Melting point | 54-58°C | | Boiling point | 504.8±50.0 °C(Predicted) | | density | 1.42 | | storage temp. | Store at RT | | solubility | DMSO: >5mg/mL | | pka | -1.87±0.40(Predicted) | | form | powder | | color | white | | optical activity | [α]/D >-70° | | CAS DataBase Reference | 262352-17-0(CAS DataBase Reference) |
| Hazard Codes | Xn | | Risk Statements | 22 | | WGK Germany | 3 |
| | Torcetrapib Usage And Synthesis |
| Chemical Properties | Off-White Low Melting Solid | | Uses | Cholesteryl ester transfer protein (CETP) inhibitor. Antilipemic; antiatherosclerotic. | | Definition | ChEBI: Torcetrapib is a member of quinolines, a carbamate ester and a member of (trifluoromethyl)benzenes. It has a role as an anticholesteremic drug and a CETP inhibitor. | | Biological Activity | torcetrapib is a cetp inhibitor with ic50 of 37 nm, elevates hdl-c and reduces nonhdl-c in plasma. inhibition of cholesteryl ester transfer protein (cetp) has been shown to have a substantial effect on plasma lipoprotein levels. | | in vitro | torcetrapib dose-dependently increases aldosterone release from h295r cells after either 24 or 48 h of treatment, this effect is mediated by calcium channel as calcium channel blockers completely blocks torcetrapib-induced corticoid release and calcium increase. torcetrapib (1 μm) significantly increases the expression of steroidogenic gene, cyp11b2 and cyp11b1, in h295r cell lines [1]. | | in vivo | researchers tested torcetrapib in rabbits fed an atherogenic diet at a dose sufficient to increase hdl-c by at least 3-fold. cetp activity was inhibited by 70–80% throughout the study. non-hdl-c increased in both groups, but there was no difference apparent by the study’s end [2]. | | storage | Room temperature | | references | [1] hu x, dietz jd, xia c, knight dr, loging wt, smith ah, yuan h, perry da, keiser j. torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition. endocrinology. 2009;150(5):2211-9.
[2] morehouse la, sugarman ed, bourassa pa, sand tm, zimetti f, gao f, rothblat gh, milici aj. inhibition of cetp activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in new zealand white rabbits. j lipid res. 2007;48(6):1263-72.
[3] barter pj, caulfield m, eriksson m, grundy sm, kastelein jj, komajda m, lopez-sendon j, mosca l, tardif jc, waters dd, shear cl, revkin jh, buhr ka, fisher mr, tall ar, brewer b; illuminate investigators. effects of torcetrapib in patients at high risk for coronary events. n engl j med. 2007;357(21):2109-22. |
| | Torcetrapib Preparation Products And Raw materials |
|